double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391-402.[
2.Emerging Modes of Treatment of IgA Nephropathy.Int J Mol Sci 2.60 ERA. Long-term renal benefit over 2 years withNefecon verified: The NefIgArd Phase 3 full trial results.
参考文献: 1. IgA nephropathy in adults — treatment standard.NDT 2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. 4.IgA nephropathy: Pathogenesis.UTD. 5.A Phas...
[5]Gentile M, Sanchez-Russo L, Riella LV, et al. Immune abnormalities in IgA nephropathy. Clin Kidney J. 2023;16(7):1059-1070. [6] WuL,DuX,LuX.RoleoftelitaciceptinthetreatmentofIgAnephropathy.EurJMedRes.2023;28(1):369. [7] LvJ,LiuL,HaoC,etal.RandomizedPhase2TrialofTelitaciceptinP...
2.Emerging Modes of Treatment of IgA Nephropathy.Int J Mol Sci 2.60 ERA. Long-term renal benefit over 2 years withNefecon verified: The NefIgArd Phase 3 full trial results. 点开下方图片,可关注、查看、搜索肾上线所有历...
参考文献 [1]肾医通公众号. [2]Locatelli F, Del Vecchio L, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy.Clin Kidney J. 2023;16(Suppl 2):ii40-ii46. Published 2023 Dec 4. doi:10.1093/ckj/sfa...
(2):391-402.Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023...
[3] Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2)...
[15]Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):...
[8]Wu L, Du X, Lu X. Role of telitacicept in the treatment of IgA nephropathy. Eur J Med Res. 2023;28(1):369. Published 2023 Sep 22. [9]Lv J, Liu L, Hao C, et al. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney...